The ratio of AST to ALT in the liver of the mRNA-treated mice was significantly reduced compared with the control group (Figure 4H), indicating that α-Gal A mRNA delivery can alleviate liver damage in Fabry disease model mice. The gene discussed is GPT; the disease is Fabry disease.